Short interest for Zivo Bioscience gives investors a sense of the degree to which investors are betting on the decline of Zivo Bioscience's stock. Short interest data is updated every two weeks.

Zivo Bioscience Stock (OTC:ZIVOW), Short Interest Report

Zivo Bioscience Inc is a research and development company operating in both the biotech and agtech sectors, with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company's candidates are; Bovine Mastitis, Canine Joint Health, Human Immune Modulation, Companion Animal Food Ingredient, NDI (New Dietary Ingredient, and Skin Health.

Zivo Bioscience Inc Warrants (29/04/2026)

Zivo Bioscience Inc

<p>Purple Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPL#NASDAQ">PRPL</a>) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Purple Innovation and provided 12-month price targets. The average target is $2.25, accompanied by a high estimate of $2.50 and a low estimate of $2.00. Witnessing a positive shift, the current average has risen by 45.16% from the previous average price target of $1.55.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715187673_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Purple Innovation. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$2.25</td>
<td>-</td>
</tr>
<tr>
<td>Matt Koranda</td>
<td>Roth MKM</td>
<td>Maintains</td>
<td>Buy</td>
<td>$2.50</td>
<td>$2.50</td>
</tr>
<tr>
<td>Matt Koranda</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$2.50</td>
<td>$2.00</td>
</tr>
<tr>
<td>Jeremy Hamblin</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Hold</td>
<td>$2.00</td>
<td>$1.00</td>
</tr>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$2.25</td>
<td>$1.25</td>
</tr>
<tr>
<td>Matt Koranda</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Neutral</td>
<td>$2.00</td>
<td>$1.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Purple Innovation. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Purple Innovation compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Purple Innovation's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Purple Innovation's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PRPL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Purple Innovation analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Purple Innovation</h2>
<p>Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms, and other products. It sells its products through online channels, traditional wholesale partners and third-party online retailers.</p>
<h3>Purple Innovation: Delving into Financials</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Purple Innovation's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>1.13%</strong> as of 31 December, 2023, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Purple Innovation's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-12.56%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Purple Innovation's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-14.79%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-4.65%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Purple Innovation's debt-to-equity ratio is below the industry average. With a ratio of <b>1.33</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

PRPL

Breaking Down Purple Innovation: 6 Analysts Share Their Views

<p>TD Cowen  analyst Dan Brennan   maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Hold and raises the price target from $350 to $358.</p>


News

Price Target

TD Cowen Maintains Hold on Waters, Raises Price Target to $358

<p>In the preceding three months, 5 analysts have released ratings for IDEAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $55.4, a high estimate of $60.00, and a low estimate of $52.00. This current average has increased by 24.02% from the previous average price target of $44.67. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715187666_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The analysis of recent analyst actions sheds light on the perception of IDEAYA Biosciences by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Driscoll</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$52.00</td>
<td>-</td>
</tr>
<tr>
<td>Yigal Nochomovitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Justin Zelin</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$57.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$53.00</td>
<td>$43.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to IDEAYA Biosciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of IDEAYA Biosciences compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for IDEAYA Biosciences's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into IDEAYA Biosciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/IDYA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on IDEAYA Biosciences analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind IDEAYA Biosciences</h2>
<p>IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.</p>
<h3>IDEAYA Biosciences's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> IDEAYA Biosciences's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately <strong>-2.49%</strong>. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> IDEAYA Biosciences's net margin is impressive, surpassing industry averages. With a net margin of <strong>-865.76%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> IDEAYA Biosciences's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-6.01%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> IDEAYA Biosciences's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-5.74%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> IDEAYA Biosciences's debt-to-equity ratio is below the industry average at <strong>0.0</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


IDYA

Unveiling 5 Analyst Insights On IDEAYA Biosciences

WIIM

DDOG

Datadog shares are trading higher after Baird upgraded the stock from Neutral to Outperform and raised its price target from $130 to $140.

<p>Financial giants have made a conspicuous bearish move on Canopy Gwth. Our analysis of options history for Canopy Gwth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) revealed 23 unusual trades.</p>
<p>Delving into the details, we found 39% of traders were bullish, while 52% showed bearish tendencies. Out of all the trades we spotted, 12 were puts, with a value of $1,232,383, and 11 were calls, valued at $549,815.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $8.0 to $28.0 for Canopy Gwth over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Canopy Gwth stands at 2738.08, with a total volume reaching 11,868.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Canopy Gwth, situated within the strike price corridor from $8.0 to $28.0, throughout the last 30 days.</p>
<h3>Canopy Gwth Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715187660_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CGC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.35</td>
<td>$4.85</td>
<td>$4.85</td>
<td>$10.00</td>
<td>$426.8K</td>
<td>246</td>
<td>1.0K</td>
</tr>
<tr>
<td>CGC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$3.1</td>
<td>$3.05</td>
<td>$3.05</td>
<td>$10.00</td>
<td>$197.9K</td>
<td>849</td>
<td>1.9K</td>
</tr>
<tr>
<td>CGC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$3.35</td>
<td>$3.05</td>
<td>$3.05</td>
<td>$10.00</td>
<td>$159.2K</td>
<td>849</td>
<td>1.9K</td>
</tr>
<tr>
<td>CGC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.54</td>
<td>$1.45</td>
<td>$1.55</td>
<td>$10.00</td>
<td>$139.5K</td>
<td>2.2K</td>
<td>125</td>
</tr>
<tr>
<td>CGC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>07/19/24</td>
<td>$3.15</td>
<td>$3.1</td>
<td>$3.1</td>
<td>$10.00</td>
<td>$120.1K</td>
<td>849</td>
<td>120</td>
</tr>
</tbody>
</table>
</p>
<h3>About Canopy Gwth</h3>
<p>Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Doja, 7ACRES, Tweed, and Deep Space. Its non-THC products include skincare products under Martha Stewart CBD and Storz &amp; Bickel vaporizers. Canopy growth is attempting to merge its U.S. assets into a separately operated holding company, Canopy USA, which will not be consolidated into the Canadian company's financials.</p>
<h3>Current Position of Canopy Gwth</h3>
<ul>
<li>With a trading volume of 5,322,531, the price of CGC is down by -4.54%, reaching $9.05.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 43 days from now.</li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Canopy Gwth with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

A Closer Look at Canopy Gwth's Options Market Dynamics

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Lululemon Athletica</strong>.</p>
<p>Looking at options history for Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) we detected 12 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 16% of the investors opened trades with bullish expectations and 66% with bearish.</p>
<p>From the overall spotted trades, 7 are puts, for a total amount of $681,997 and 5, calls, for a total amount of $249,222.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $320.0 and $400.0 for Lululemon Athletica, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Lululemon Athletica's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Lululemon Athletica's significant trades, within a strike price range of $320.0 to $400.0, over the past month.</p>
<h3>Lululemon Athletica Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715187655_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>LULU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$20.45</td>
<td>$20.1</td>
<td>$20.4</td>
<td>$330.00</td>
<td>$306.0K</td>
<td style="text-align: right;">359</td>
<td style="text-align: right;">154</td>
</tr>
<tr>
<td>LULU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$34.95</td>
<td>$34.55</td>
<td>$34.55</td>
<td>$360.00</td>
<td>$107.1K</td>
<td style="text-align: right;">225</td>
<td style="text-align: right;">36</td>
</tr>
<tr>
<td>LULU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$43.0</td>
<td>$42.7</td>
<td>$42.7</td>
<td>$360.00</td>
<td>$81.1K</td>
<td style="text-align: right;">647</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>LULU</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$43.6</td>
<td>$42.5</td>
<td>$43.0</td>
<td>$360.00</td>
<td>$77.4K</td>
<td style="text-align: right;">245</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>LULU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$40.9</td>
<td>$40.35</td>
<td>$40.9</td>
<td>$380.00</td>
<td>$73.6K</td>
<td style="text-align: right;">147</td>
<td style="text-align: right;">2</td>
</tr>
</tbody>
</table>
</p>
<h3>About Lululemon Athletica</h3>
<p>Lululemon Athletica designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 700 company-owned stores in about 20 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.</p>
<p>Following our analysis of the options activities associated with Lululemon Athletica, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Lululemon Athletica</h3>
<ul>
<li>Currently trading with a volume of 550,478, the LULU's price is down by -0.66%, now at $347.53. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 22 days.</li>
</ul>
<h3>What The Experts Say On Lululemon Athletica</h3>
<p>3 market experts have recently issued ratings for this stock, with a consensus target price of $456.6666666666667.</p>
<ul>
<li>An analyst from Piper Sandler has decided to maintain their Overweight rating on Lululemon Athletica, which currently sits at a price target of $470. </li>
<li>An analyst from Baird persists with their Outperform rating on Lululemon Athletica, maintaining a target price of $505. </li>
<li>An analyst from Barclays downgraded its action to Equal-Weight with a price target of $395. </li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Lululemon Athletica with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


LULU

Lululemon Athletica Unusual Options Activity For May 08

<p>Avient (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVNT#NYSE">AVNT</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $51.0, a high estimate of $53.00, and a low estimate of $49.00. Surpassing the previous average price target of $47.25, the current average has increased by 7.94%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715187656_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The perception of Avient by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$52.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Vincent Anderson</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$53.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Kristen Owen</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$49.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Avient. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Avient compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Avient's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Avient's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AVNT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Avient analyst ratings.</strong></a></p>
<h2>Delving into Avient's Background</h2>
<p>Avient Corp manufactures and sells a variety of chemical and plastic-based products to designers and processors of plastics. The firm operates in two segments: Color, Additives and Inks, and Specialty Engineered Materials. The company's product portfolio includes concentrated color and ink blends, plastic resins, and various specialized polymer materials used in industries such as food packaging, construction, transportation, cosmetics, and healthcare. The color, additives, &amp; ink segment and the distribution segment together generate a vast majority of revenue. More than half of the total revenue is derived from the United States.</p>
<h3>Avient: A Financial Overview</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Avient faced challenges, resulting in a decline of approximately <strong>-9.03%</strong> in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Materials sector.</p>
<p><strong>Net Margin:</strong> Avient's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.98%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Avient's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>1.24%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Avient's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.49%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Avient's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.92</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AVNT

Critical Insights From Avient Analyst Ratings: What You Need To Know

<p>Benzinga's options scanner just detected over 12 options trades for <strong>UiPath</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) summing a total amount of $334,809.</p>
<p>At the same time, our algo caught 10 for a total amount of 316,569.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $20.0 and $24.0 for UiPath, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in UiPath's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to UiPath's substantial trades, within a strike price spectrum from $20.0 to $24.0 over the preceding 30 days.</p>
<h3>UiPath Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715187650_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PATH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$1.3</td>
<td>$1.29</td>
<td>$1.3</td>
<td>$22.00</td>
<td>$49.1K</td>
<td>1.5K</td>
<td>205</td>
</tr>
<tr>
<td>PATH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$2.08</td>
<td>$2.05</td>
<td>$2.06</td>
<td>$20.00</td>
<td>$37.2K</td>
<td>2.5K</td>
<td>1.0K</td>
</tr>
<tr>
<td>PATH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$2.08</td>
<td>$2.06</td>
<td>$2.06</td>
<td>$20.00</td>
<td>$35.4K</td>
<td>2.5K</td>
<td>615</td>
</tr>
<tr>
<td>PATH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$4.8</td>
<td>$4.7</td>
<td>$4.7</td>
<td>$24.00</td>
<td>$34.7K</td>
<td>1.1K</td>
<td>43</td>
</tr>
<tr>
<td>PATH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$2.08</td>
<td>$2.06</td>
<td>$2.06</td>
<td>$20.00</td>
<td>$33.7K</td>
<td>2.5K</td>
<td>139</td>
</tr>
</tbody>
</table>
</p>
<h3>About UiPath</h3>
<p>UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, the right to access certain software products it hosts (i.e., SaaS) and professional services. It generates a majority of its revenues from the Americas followed by Europe, Middle East, and Africa and Asia-Pacific.</p>
<p>Having examined the options trading patterns of UiPath, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>UiPath's Current Market Status</h3>
<ul>
<li>With a trading volume of 2,098,469, the price of PATH is down by -1.42%, reaching $19.73.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 14 days from now.</li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for UiPath, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


PATH

A Closer Look at UiPath's Options Market Dynamics

<p>During the last three months, 9 analysts shared their evaluations of Clear Secure (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOU#NYSE">YOU</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Clear Secure and provided 12-month price targets. The average target is $33.11, accompanied by a high estimate of $40.00 and a low estimate of $21.00. Witnessing a positive shift, the current average has risen by 16.18% from the previous average price target of $28.50.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715187643_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The standing of Clear Secure among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$21.00</td>
<td>-</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$21.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$34.00</td>
<td>-</td>
</tr>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$34.00</td>
<td>-</td>
</tr>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$34.00</td>
<td>-</td>
</tr>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Clear Secure. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Clear Secure compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Clear Secure's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Clear Secure's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/YOU/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Clear Secure analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>About Clear Secure</h2>
<p>Clear Secure Inc is an identity company making experiences safer and easier digitally and physically. It is involved in the creation of a frictionless travel experience while enhancing security. Its secure identity platform uses biometrics to automate the identity verification process through lanes in airports which helps to make the travel experience safe and easy.</p>
<h3>Clear Secure: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Clear Secure displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately <strong>33.3%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Clear Secure's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>8.17%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Clear Secure's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>5.49%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.33%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Clear Secure's debt-to-equity ratio is below the industry average at <strong>0.55</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Decoding 9 Analyst Evaluations For Clear Secure

<p>In the preceding three months, 4 analysts have released ratings for Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Premier and provided 12-month price targets. The average target is $21.88, accompanied by a high estimate of $22.50 and a low estimate of $21.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 13.62%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715187623_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The perception of Premier by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$21.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$22.50</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Premier. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Premier compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Premier's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Premier's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PINC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Premier analyst ratings.</strong></a></p>
<h2>Get to Know Premier Better</h2>
<p>Premier Inc is a Charlotte, North Carolina-based national group purchasing organization providing primary supply chain services to large hospital systems and more recently to alternate outpatient locations as it expands its footprint. Through acquisitions, the company also offers a compliment of advisory services and consulting services along with software-as-a-service-based subscriptions. The company's revenue is all sourced domestically and is reported in two business segments: the core supply chain services (approximately 70% of fiscal 2019 revenue) and the consulting and technology platform of performance services (approximately 30%).</p>
<h3>Premier: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Premier's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately <strong>-6.92%</strong> in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Premier's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>16.22%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Premier's ROE excels beyond industry benchmarks, reaching <strong>2.29%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Premier's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.41%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Premier's debt-to-equity ratio is below the industry average. With a ratio of <b>0.07</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PINC

Unveiling 4 Analyst Insights On Premier

<p>Imagine having a <a href="https://www.benzinga.com/personal-finance/financial-advisors/24/01/36745933/how-much-cash-can-i-get-each-month-from-a-1-5-million-annuity">reliable source of income</a> you can count on throughout your <a href="https://www.benzinga.com/money/how-much-do-i-need-to-retire">retirement</a>. That&#8217;s the promise of an annuity. These insurance products have been designed to turn your savings into a steady stream of monthly payments. They guarantee peace of mind and financial security in your golden years.&nbsp;</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich-advisor"><strong>Are you rich?</strong></a><strong> Here&#8217;s what Americans think you need to be considered wealthy.</strong></li>
<li><strong>Can you guess how many Americans successfully retire with $1,000,000 saved?</strong><a href="https://www.benzinga.com/money/red-ventures"><strong> </strong><strong>The percentage may shock you</strong></a><strong>.</strong></li>
</ul>
<p>Annuities come in various options — from fixed rates to those tied to market performance. But the key question remains: with $300,000 to invest, how much monthly income can a realistic annuity generate?</p>
<h2 class="wp-block-heading">Immediate vs. Deferred Annuities</h2>
<p>The <a href="https://www.benzinga.com/money/best-annuity-companies">type of annuity</a> you choose can significantly impact your monthly income. With a $300,000 fixed immediate annuity, a 65-year-old man could receive around $1,450 to $1,950 per month for life, while a 65-year-old woman may get $1,800 to $2,200 per month. These payments are guaranteed for as long as the annuitant lives.</p>
<p>On the other hand, a deferred income annuity allows you to delay the start of your payments, often until a later age like 75 or 80. By deferring the income, you can potentially receive higher monthly payments. For example, a 65-year-old man who invests $300,000 in a deferred income annuity with income starting at age 80 could receive around $4,000 per month for life, while a woman of the same age could receive about $3,500 per month.</p>
<h2 class="wp-block-heading">Qualified Longevity Annuity Contracts (QLACs)</h2>
<p>Qualified Longevity Annuity Contracts are a type of deferred income annuity that can be purchased with pretax retirement assets like <a href="https://www.benzinga.com/money/roth-ira-vs-401k">401(k)s and IRAs</a>. With a QLAC, you can invest up to 25% of your retirement account balance or $200,000, whichever is less, to provide income starting as late as age 85. This can help manage required minimum distributions (RMDs). They also provide a foundation of guaranteed income in the later years of retirement.</p>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<p><strong>Trending: </strong><strong>82% of Americans aren&#8217;t using</strong><a href="https://www.benzinga.com/money/public-hys"><strong> </strong><strong>this government secured 5% passive income stream</strong></a><strong>, are you one of them?</strong></p>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h2 class="wp-block-heading">Additional Factors To Consider</h2>
<p>While the type of annuity plays a significant role, several additional factors influence the <a href="https://www.benzinga.com/personal-finance/24/05/38675296/suze-orman-says-you-should-be-putting-every-single-cent-into-a-roth-retirement-account-if-not-yo">amount of income</a> you can expect to receive:</p>
<ul>
<li>Your age and gender: Generally, older individuals and women (due to their longer life expectancies) receive higher payouts.</li>
</ul>
<ul>
<li>Payout option: Lifetime income options typically come with slightly lower payouts compared to options that include provisions for beneficiaries if you pass away before a set period. </li>
</ul>
<ul>
<li>Interest rates: The prevailing economic climate, particularly interest rates, can affect annuity returns. Higher interest rates can translate into more attractive income streams.</li>
</ul>
<h2 class="wp-block-heading">Important Considerations Before You Invest</h2>
<p>Annuities can be a powerful tool for retirement income, but before you invest, here are some important factors to consider:</p>
<p>Fees: Some annuities come with fees that can eat into your overall returns. Be sure to understand the fee structure before making a decision.</p>
<p>Inflation: Fixed annuity payments won&#8217;t keep pace with inflation over time. That is, their purchasing power may diminish in the long run.</p>
<p>Company Strength: Choose an annuity from a financially sound and reputable insurance company. This will ensure the safety of your investment. You can use resources from organizations like A.M. Best to check an insurer&#8217;s financial strength.</p>
<p><a href="https://www.benzinga.com/money/smartasset">Consult with a financial adviser</a>, if you want to make sure you&#8217;re on the right track with your retirement savings. They can also help you to explore how annuities might fit into your overall plan. They also provide personalized guidance on your savings, analyze different annuity options, and ensure any annuity investment strategically aligns with your retirement income goals.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>The average American couple has saved this much money for retirement —</strong><a href="http://www.benzinga.com/money/smartasset"><strong> </strong><strong>How do you compare</strong></a><strong>?</strong></li>
<li><strong>Can living off interest from a</strong><a href="http://www.benzinga.com/money/smartasset"><strong> </strong><strong>$1 million investment support my retirement dreams</strong></a><strong>?</strong></li>
</ul>
<p><em>&#x2A;This information is not financial advice, and personalized guidance from a financial adviser is recommended for making well-informed decisions.</em></p>
<p><em>Jeannine Mancini has written about personal finance and investment for the past 13 years in a variety of publications including Zacks, The Nest, and eHow. She is not a licensed financial adviser, and the content herein is for information purposes only and is not, and does not constitute or intend to constitute, investment advice or any investment service. While Mancini believes the information contained herein is reliable and derived from reliable sources, there is no representation, warranty, or undertaking, stated or implied, as to the accuracy or completeness of the information.</em></p>


Personal Finance

How Much Cash Can A $300,000 Annuity Generate For Me Each Month?

<p>Lucid Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $3.55, along with a high estimate of $4.50 and a low estimate of $2.90. A 32.89% drop is evident in the current average compared to the previous average price target of $5.29. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715187614_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Lucid Gr by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$3.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Itay Michaeli</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$2.90</td>
<td>-</td>
</tr>
<tr>
<td>Adam Jonas</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Tom Narayan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$3.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$4.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Ben Kallo</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$4.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>John Murphy</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$4.50</td>
<td>$7.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$4.00</td>
<td>$6.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Lucid Gr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Lucid Gr compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Lucid Gr's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Lucid Gr's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LCID/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Lucid Gr analyst ratings.</strong></a></p>
<h2>Discovering Lucid Gr: A Closer Look</h2>
<p>Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.</p>
<h3>A Deep Dive into Lucid Gr's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Lucid Gr's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>15.6%</strong> as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Lucid Gr's net margin is impressive, surpassing industry averages. With a net margin of <strong>-396.41%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Lucid Gr's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-15.08%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Lucid Gr's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-7.87%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Lucid Gr's debt-to-equity ratio is below the industry average at <strong>0.57</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


LCID

Decoding 8 Analyst Evaluations For Lucid Gr

Trading Ideas

NFLX

CNBC Halftime Report Final Trades: Netflix, NexaEnergy

<p>Canaccord Genuity  analyst Jon Young   maintains Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Hold and lowers the price target from $46 to $43.</p>


STAA

Canaccord Genuity Maintains Hold on Staar Surgical, Lowers Price Target to $43

AFRM

Affirm shares are trading lower amid volatility after the company reported Q3 financial results.

<p><strong>Sunoco LP</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUN#NYSE">SUN</a>) shares are trading higher after it reported&nbsp;first-quarter FY24 revenues&nbsp;of $5.50 billion, which&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/n38695506/sunoco-lp-announces-first-quarter-2024-financial-and-operating-results" rel="noreferrer noopener">exceeded the consensus of $5.23 billion</a>.</p>
<p>The partnership sold over 2.1 billion gallons of fuel (+9% Y/Y), with the fuel margin for all gallons sold at 11.7 cents per gallon (vs 12.9 cents per gallon in the prior year quarter).</p>
<p>Adjusted distributable cash flow of $176 million was higher than $160 million a year ago.</p>
<p>Adjusted EBITDA increased to $242 million from $221 million a year ago. EPS of $2.26 surpassed&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of $1.22</a>.</p>
<p>Total capital expenditures were $41 million, including&nbsp;$27 million&nbsp;for growth capital and&nbsp;$14 million&nbsp;for maintenance capital.</p>
<p><strong>Distribution:&nbsp;</strong>On May 3, Sunoco&nbsp;quarterly increased distribution by 4% to $0.8756&nbsp;per unit, payable on May 20 to unitholders of record as of May 13.</p>
<p>As of&nbsp;March-end, the company had a long-term debt of&nbsp;$3.8 billion. The partnership maintained liquidity of approximately&nbsp;$870 million&nbsp;at the end of the quarter under its&nbsp;$1.5 billion&nbsp;revolving credit facility.&nbsp;&nbsp;</p>
<p><strong>Outlook</strong>: Sunoco revised FY24 guidance for adjusted EBITDA to $1.46 billion&nbsp;to&nbsp;$1.52 billion, reflecting NuStar and Zenith acquisitions and divestiture.</p>
<p>In January 2024, the company disclosed a deal&nbsp;for selling&nbsp;204 convenience stores to 7-Eleven for around $1 billion, including customary fuel and<a target="_blank" href="https://www.benzinga.com/markets/equities/24/01/36594233/sunocos-strategic-moves-1b-7-eleven-deal-european-terminals-acquisition-growth-focus" rel="noreferrer noopener">&nbsp;merchandise&nbsp;inventory adjustments</a>.&nbsp;</p>
<p>The NuStar&nbsp;deal is projected to boost Sunoco&#8217;s stability and credit profile and&nbsp;expects&nbsp;to realize at least&nbsp;$150 million&nbsp;in&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/n38612604/sunoco-lp-completes-acquisition-of-nustar-energy-l-p-announces-a-4-increase-in-quarterly-distribut" rel="noreferrer noopener">expenses and commercial synergies</a>.&nbsp;</p>
<p>Investors can gain exposure to the stock via&nbsp;<strong>InfraCap MLP ETF</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMZA#NYSE">AMZA</a>) and&nbsp;<strong>Global X MLP ETF</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLPA#NYSE">MLPA</a>).</p>
<p><strong>Price Action</strong>: Sunoco shares are trading up by 0.22% at $55.71 at the last check Wednesday. </p>
<p><em>Photo via Shutterstock</em></p>


Earnings

Equities

Guidance

AMZA

MLPA

Sunoco Spills the Beans: Big Beat, Higher Payout, & Brighter Outlook

<p>TD Cowen  analyst Tara Bancroft   maintains Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) with a Hold and lowers the price target from $11 to $7.</p>


OCUL

TD Cowen Maintains Hold on Ocular Therapeutix, Lowers Price Target to $7

<p>Canaccord Genuity  analyst Maria Ripps   maintains Vivid Seats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEAT#NASDAQ">SEAT</a>) with a Buy and lowers the price target from $12 to $10.</p>


SEAT

Canaccord Genuity Maintains Buy on Vivid Seats, Lowers Price Target to $10

<p>TD Cowen  analyst Robert Moskow   maintains WK Kellogg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) with a Hold and raises the price target from $13 to $24.</p>


TD Cowen Maintains Hold on WK Kellogg, Raises Price Target to $24

<p><strong>Mullen Automotive, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) shares are trading higher Wednesday, and the stock is up by more than 50% over the past five days. Here's a <a href="https://www.benzinga.com/news/24/05/38649364/why-mullen-automotive-shares-are-moving-higher-today">look at what's going on.&nbsp;</a></p>
<p><strong>What To Know:</strong></p>
<p>Mullen <a href="https://www.benzinga.com/pressreleases/24/05/g38642437/mullen-signs-agreement-with-california-based-and-hvip-approved-national-auto-fleet-group">announced</a> on Monday the addition of a commercial dealer, <strong>National Auto Fleet Group</strong>, which will offer Mullen&#8217;s full line of all-electric commercial vehicles in two California locations.</p>
<p>The company said on Tuesday its subsidiary, <strong>Bollinger Motors</strong>, and <strong>Amerit Fleet Solutions</strong> have entered into <a href="https://www.benzinga.com/pressreleases/24/05/g38668775/mullen-announces-bollinger-motors-taps-amerit-fleet-solutions-for-mobile-service-and-warranty-for-">an agreement </a>for Amerit to provide mobile service and maintenance to Bollinger&#8217;s commercial fleet customers. </p>
<p>Mullen shares are blasting higher on heavy trading volume Wednesday. According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, more than 13.5 million shares have already been traded in the session, compared to the stock&#8217;s 100-day average of 3.5 million shares.</p>
<p>Approximately, 24.2% of Mullen shares are being sold short which can contribute to large price moves when combined with news catalysts and heavy trading volume.&nbsp;</p>
<p><em>Related News: </em><a href="https://www.benzinga.com/news/earnings/24/05/38683061/reddit-shares-soar-on-first-post-ipo-q1-results-strong-q2-guidance"><em>Reddit Shares Soar On First Post-IPO Q1 Results, Strong Q2 Guidance</em></a></p>
<h2 class="wp-block-heading">How To Buy MULN Stock:</h2>
<p>By now you're likely curious about how to participate in the market for Mullen Automotive  &#8211; be it to purchase shares, or even attempt to bet against the company.</p>
<p>Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. </p>
<p>In the the case of Mullen Automotive, which is trading at $7.73 as of publishing time, $100 would buy you 12.94 shares of stock.</p>
<p>If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.</p>
<p><strong>MULN Price Action:</strong> According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Mullen Automotive shares are up 29.1% at $7.41 at the time of publication Wednesday.</p>
<p><em>Image: Courtesy of Mullen Automotive, Inc.</em></p>
